MAIA - MAIA Biotechnology, Inc. Short-Term Debt to Capital

Symbol and logo of brand MAIA Biotechnology Inc (MAIA)

The market trend for MAIA Biotechnology (MAIA) helps analyze the financial stability of the company, which attracts top biochemists with ambitious goals and stock options to create targeted agents against telomeres. The current indicator is 0.00. The business relies on strict temperature control during the delivery of medications to centers. Additionally, automated data analysis systems and screening robots are being implemented to accelerate clinical trials.

Current Liabilities to Capital: MAIA Biotechnology Inc (MAIA) for 04/28/2023 - 10/29/2026

Summary analytical data breakdowns for MAIABiotech.com (MAIA)

- stock value and consensus price forecast:
Price Chart MAIA Biotechnology Inc|MAIA - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization MAIA Biotech|MAIA - Real Price to Acquire Entire Company
- book capitalization information:
Net Assets per Single Share MAIA Biotechnology|MAIA - Total Stockholders' Equity|Market Value to Book Value Ratio MAIABiotech.com|MAIA - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity MAIA Biotechnology|MAIA - Long-Term Liabilities to Capital|Short-Term Debt to Capital MAIA Biotechnology, Inc.|MAIA - Company Total Indebtedness|Debt to Book Value MAIA Biotech|MAIA - Long-Term Debt|Company Current Liabilities MAIA Biotechnology
Initial company analysis:MAIA Biotechnology Inc MAIA
Signature product of MAIABiotech.com

This indicator assesses the proportion of liabilities maturing within one year relative to equity, determining the current debt load and liquidity risk. By analyzing the short-term debt-to-market cap chart on GURU.Markets, an investor can see the actual leverage, which is critical for MAIA Biotechnology (MAIA) due to a lack of asset diversification and total dependence on the outcome of a single clinical trial.

Competitors of MAIA Biotechnology (MAIA)

Short-Term Debt to Equity ImmunityBio Corp (IBRX)|Immunocore Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital JANX (Janux Therapeutics)|RCUS - Short-Term Debt to Equity Ratio|ZYME - Short-Term Debt to Equity|Current Liabilities to Capital Tango Therapeutics Inc|Iovance (IOVA) - Short-Term Debt to Equity|IMTX (Immatics Biotechnologies) - Short-Term Debt to Equity|Short-Term Debt to Equity Xencor, Inc.|Current Liabilities to Capital compasstherapeutics.com CMPX|Short-Term Debt to Capital REPL|Lyell (LYEL) - Short-Term Indebtedness to Equity|Innate Pharma, S.A. - Short-Term Debt to Equity Ratio|Pyxis Oncology Inc. (PYXS) - Current Liabilities to Capital|CGEN: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital IOBT (iobiotech.com)|STRO: Short-Term Debt to Capital|INKT - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Werewolf Therapeutics Inc.|Short-Term Debt to Equity Ratio Immix (IMMX)|Short-Term Debt to Equity ALX Oncology (ALXO)|Short-Term Debt to Equity Ratio Cue Biopharma Inc. CUE|PDS Biotechnology Corporation - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Sonnet BioTherapeutics Holdings, Inc. SONN|LIMN - Short-Term Debt to Equity|LVTX (LAVA Therapeutics N.V.) - Short-Term Debt to Capital Ratio|NextCure, Inc. (NXTC) - Short-Term Debt to Equity|Current Liabilities to Capital Leap Therapeutics (LPTX)|Short-Term Debt to Equity Ratio INTS|SNSE - Short-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio TOVX (Synthetic Biologics)|Short-Term Loans to Capital Ratio GRTS|Short-Term Debt to Capital KA (Kineta, Inc.)|Ratio of Short-Term Indebtedness to Capital NEXI|Turnstone Biologics Corporation - Short-Term Debt to Capital|Current Liabilities to Capital Vaccinex Inc.|Harpoon Tx (HARP) - Short-Term Debt to Equity